VEGF: NPS faces its rat challenge

Although NPS Pharmaceuticals Inc. already has advanced its ALX1-11 human parathyroid hormone into Phase III trials for osteoporosis, the company is about to begin the rat experiments that caused Eli Lilly and Co. to call an early halt to a pivotal trial of its Forteo PTH fragment in December 1998, after seeing evidence of osteosarcoma in the animals.

While NPSP will have

Read the full 610 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers